Literature DB >> 8270588

Use of low-dose fluoxetine in major depression and panic disorder.

A K Louie1, T B Lewis, R A Lannon.   

Abstract

BACKGROUND: Recent reports suggest that fluoxetine in doses less than the standard 20 mg/day may be effective in the treatment of depression and that some patients, particularly those with panic disorder, may be intolerant of the 20 mg/day dose. We examined the utility of starting fluoxetine at a low daily dose (5 mg) and increasing to the standard daily dose (20 mg) in depressed outpatients with and without concurrent panic disorder.
METHOD: One hundred thirty-three consecutive outpatients meeting DSM-III-R criteria for major depression were studied. Patients were started on fluoxetine 5 mg/day and were gradually increased to 20 mg/day over a 1-week period. Patients who were unable to reach the 20 mg/day dose were instructed to take the highest tolerable dose for the duration of the study. After a month of fluoxetine treatment, patients were evaluated for compliance with treatment and improvement on the Clinical Global Improvement scale.
RESULTS: Twenty-eight percent of the patients were unable to increase the dose to the full 20 mg. Of these patients, half could not tolerate doses lower than 20 mg and discontinued the drug, while the other half did well clinically on the lower doses. Patients who discontinued fluoxetine tended to have panic disorder in addition to depression.
CONCLUSION: We conclude that starting fluoxetine at doses lower than 20 mg is a useful strategy because of the substantial fraction of patients who cannot tolerate a 20-mg dose but appear to benefit from lower doses. This dosing strategy may be of particular benefit for patients with panic disorder.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8270588

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  11 in total

1.  Time to response in panic disorder in a naturalistic setting: combination therapy with alprazolam orally disintegrating tablets and serotonin reuptake inhibitors compared to serotonin reuptake inhibitors alone.

Authors:  David J Katzelnick; Johnaqa Saidi; Mark R Vanelli; James W Jefferson; James M Harper; Kay E McCrary
Journal:  Psychiatry (Edgmont)       Date:  2006-12

2.  Serum BDNF levels before treatment predict SSRI response in depression.

Authors:  Owen M Wolkowitz; Jessica Wolf; Wendy Shelly; Rebecca Rosser; Heather M Burke; George K Lerner; Victor I Reus; J Craig Nelson; Elissa S Epel; Synthia H Mellon
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2011-07-03       Impact factor: 5.067

Review 3.  Risks and benefits of selective serotonin reuptake inhibitors in the treatment of depression.

Authors:  P Mourilhe; P E Stokes
Journal:  Drug Saf       Date:  1998-01       Impact factor: 5.606

Review 4.  The Black Book of Psychotropic Dosing and Monitoring.

Authors:  Alan F Schatzberg; DeBattista Charles
Journal:  Psychopharmacol Bull       Date:  2018-01-15

5.  Determinants of pharmacodynamic trajectory of the therapeutic response to paroxetine in Japanese patients with panic disorder.

Authors:  Shin Ishiguro; Takashi Watanabe; Mikito Ueda; Yoshinori Saeki; Yuki Hayashi; Kazufumi Akiyama; Atsushi Saito; Kazuko Kato; Yoshimasa Inoue; Kazutaka Shimoda
Journal:  Eur J Clin Pharmacol       Date:  2011-06-19       Impact factor: 2.953

6.  Mixed Anxiety and Depression : Diagnosis and Treatment Options.

Authors:  D Bakish; R Habib; C L Hooper
Journal:  CNS Drugs       Date:  1998-04       Impact factor: 5.749

7.  Moclobemide versus fluoxetine for a major depressive episode.

Authors:  C Reynaert; M Parent; J Mirel; P Janne; L Haazen
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

8.  A risk-benefit assessment of pharmacological treatments for panic disorder.

Authors:  J A Bennett; M Moioffer; S P Stanton; M Dwight; P E Keck
Journal:  Drug Saf       Date:  1998-06       Impact factor: 5.606

9.  Genetic and pharmacokinetic factors affecting the initial pharmacotherapeutic effect of paroxetine in Japanese patients with panic disorder.

Authors:  Yoshinori Saeki; Takashi Watanabe; Mikito Ueda; Atsushi Saito; Kazufumi Akiyama; Yoshimasa Inoue; Genta Hirokane; Sachiyo Morita; Naoto Yamada; Kazutaka Shimoda
Journal:  Eur J Clin Pharmacol       Date:  2009-03-04       Impact factor: 2.953

10.  Factors affecting discontinuation of initial treatment with paroxetine in panic disorder and major depressive disorder.

Authors:  Akiko Aoki; Shin Ishiguro; Takashi Watanabe; Mikito Ueda; Yuki Hayashi; Kazufumi Akiyama; Kazuko Kato; Yoshimasa Inoue; Shoko Tsuchimine; Norio Yasui-Furukori; Kazutaka Shimoda
Journal:  Neuropsychiatr Dis Treat       Date:  2014-09-18       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.